PMID: 9552709Jan 1, 1997Paper

A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome

International Journal of Antimicrobial Agents
I M HoepelmanM Rozenberg-Arska

Abstract

The efficacy and safety of a 3-day regimen of azithromycin prescribed in the new tablet form and of a 10-day regimen of amoxycillin clavulanic acid (co-amoxiclav, Augmentin) were compared in patients with acute lower respiratory tract infections. Of the 144 enrolled patients, 123 had a Type 1 acute exacerbation of chronic bronchitis (AECB), three patients had pneumonia, and 18 had purulent bronchitis. Treatment was successful, defined as cure or major improvement on day 14, in 59/62 (95%) patients in the azithromycin treatment group compared with 54/61 (90%) patients in the co-amoxiclav. At 30 days, the incidence of success was 77% (48/62) in the azithromycin treated group, compared with 66% (40/61) of co-amoxiclav-treated patients. At 60 days, incidences were 66% (41/62) and 59% (36/61), respectively. Several pathogens were isolated: Haemophilus influenzae in 21 patients (minimum inhibitory concentration (MIC) range for azithromycin 0.12-4 mg/l; co-amoxiclav 0.25-4 mg/l); Streptococcus pneumoniae in nine (MIC azithromycin < or = 0.06 > or = 256 mg/l; co-amoxiclav < or = 0.06-1 mg/l); and Moraxella catarrhalis in 11 (MIC azithromycin < or =0.06-2 mg/l; co-amoxiclav < or = 0.06-0.5 mg/l). Microbiological response rates were comp...Continue Reading

References

Mar 13, 1975·The New England Journal of Medicine·I Tager, F E Speizer
May 1, 1991·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·P BalmesR Poirier
Jun 1, 1991·Antimicrobial Agents and Chemotherapy·E Azoulay-DupuisJ J Pocidalo
Aug 1, 1988·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·H C NeuP Labthavikul
Feb 1, 1987·Annals of Internal Medicine·N R AnthonisenN A Nelson
May 1, 1995·International Journal of Antimicrobial Agents·I M Hoepelman, M M Schneider

❮ Previous
Next ❯

Citations

Sep 24, 2002·Lancet·UNKNOWN Pakistan Multicentre Amoxycillin Short Course Therapy (MASCOT) pneumonia study group
Nov 1, 2001·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·J M McCarty, P F Pierce
Sep 5, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lionel A Mandell, Thomas M File
May 1, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Peter E PertelJeff Alder
Apr 11, 2006·American Journal of Respiratory and Critical Care Medicine·Mirjam Christ-CrainBeat Müller
Jul 15, 2006·Médecine et maladies infectieuses·P-R Burgel
Feb 10, 2007·Current Medical Research and Opinion·Mark GotfriedGerard F Notario
Oct 13, 2005·Expert Opinion on Pharmacotherapy·F BlasiL Allegra
Jun 27, 2002·Expert Opinion on Investigational Drugs·Lisa L DeverW G Johanson
Jul 1, 2005·Treatments in Respiratory Medicine·Sat Sharma, Nicholas Anthonisen
Apr 10, 2010·Expert Review of Anti-infective Therapy·Sanjay Sethi
Oct 11, 2014·The Cochrane Database of Systematic Reviews·Smita PakhaleLise M Bjerre
Mar 10, 2015·The Cochrane Database of Systematic Reviews·Malinee LaopaiboonKyaw Swa Mya
Nov 17, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas M File
Jun 6, 2000·The Journal of Antimicrobial Chemotherapy·A J MatuteI M Hoepelman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.